| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA4362207 | B | Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method | Homo sapiens | 16 | assay format | Scientific Literature | ||
| 2. | ALA4362208 | B | Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method | Homo sapiens | 16 | assay format | Scientific Literature | ||
| 3. | ALA4362209 | B | Selectivity index, ratio of IC50 for N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system to IC50 for N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system | Homo sapiens | 1 | assay format | Scientific Literature | ||
| 4. | ALA4362210 | A | Cytotoxicity against human A549 cells assessed as inhibition of cell growth at 0.5 uM after 48 hrs under normoxic condition by CCk-8 assay relative to control | Homo sapiens | 8 | cell-based format | Scientific Literature | ||
| 5. | ALA4362211 | A | Cytotoxicity against human NCI-H446 cells assessed as inhibition of cell growth at 0.5 uM after 48 hrs under normoxic condition by CCk-8 assay relative to control | Homo sapiens | 8 | cell-based format | Scientific Literature | ||
| 6. | ALA4362212 | F | Antiproliferative activity against human A549 cells assessed as inhibition of cell growth at 0.5 uM after 48 hrs under hypoxic condition (200 uM CoCl2) by CCk-8 assay relative to control (Rvb = 59.94%) | Homo sapiens | 8 | cell-based format | Scientific Literature | ||
| 7. | ALA4362213 | F | Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth at 0.5 uM after 48 hrs under hypoxic condition (200 uM CoCl2) by CCk-8 assay relative to control (Rvb = 65.84%) | Homo sapiens | 8 | cell-based format | Scientific Literature | ||
| 8. | ALA4362214 | F | Antiproliferative activity against human A549 cells assessed as inhibition of cell growth at 0.5 uM in hypoxia condition (200 uM CoCl2) and under irradiation at 8 Gy for 24 hrs and measured after 24 hrs by CCK8 assay (Rvb = 64.135%) | Homo sapiens | 8 | cell-based format | Scientific Literature | ||
| 9. | ALA4362215 | F | Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth at 0.5 uM in hypoxia condition (200 uM CoCl2) and under irradiation at 8 Gy for 24 hrs and measured after 24 hrs by CCK8 assay (Rvb = 68.77%) | Homo sapiens | 8 | cell-based format | Scientific Literature | ||
| 10. | ALA4362216 | F | Antiproliferative activity against human A549 cells assessed as hypoxic sensitive enhancement ratio in presence of CoCl2 | Homo sapiens | 8 | cell-based format | Scientific Literature | ||
| 11. | ALA4362217 | F | Antiproliferative activity against human A549 cells assessed as hypoxic sensitive enhancement ratio in presence of Cocl2 under irradiation | Homo sapiens | 8 | cell-based format | Scientific Literature | ||
| 12. | ALA4362218 | A | Downregulation of VEGF expression in human A549 cells at 5 uM after 24 hrs under normoxic condition by q-PCR analysis relative to control | Homo sapiens | 3 | cell-based format | Scientific Literature | ||
| 13. | ALA4362219 | F | Downregulation of VEGF expression in human A549 cells at 5 uM after 24 hrs under hypoxic condition by q-PCR analysis relative to control | Homo sapiens | 3 | cell-based format | Scientific Literature | ||
| 14. | ALA4362220 | F | Antitumour activity against human A549 cells xenografted in Balb/c mouse assessed as tumour growth inhibition at 10 mg/kg, po administered daily and mesured at day 17 relative to control | Homo sapiens | 3 | organism-based format | Scientific Literature | ||
| 15. | ALA4362221 | F | Antitumour activity against human A549 cells xenografted in Balb/c mouse assessed as increase in tumour volume at 10 mg/kg, po administered daily and mesured after 7 days | Homo sapiens | 3 | organism-based format | Scientific Literature | ||
| 16. | ALA4362222 | F | Antitumour activity against human A549 cells xenografted in po dosed Balb/c mouse assessed as tumour growth inhibition administered daily for 18 days and measured every day | Homo sapiens | 2 | organism-based format | Scientific Literature | ||
| 17. | ALA4362223 | F | Antitumour activity against human A549 cells xenografted in Balb/c mouse assessed as tumour growth inhibition at 50 mg/kg, po administered daily and measured at day 18 relative to control | Homo sapiens | 2 | organism-based format | Scientific Literature | ||
| 18. | ALA4362224 | F | Antitumour activity against human A549 cells xenografted in Balb/c mouse assessed as tumour growth inhibition at 5 mg/kg, po administered daily and measured at day 18 relative to control | Homo sapiens | 2 | organism-based format | Scientific Literature | ||
| 19. | ALA4362225 | F | Antitumour activity against human A549 cells xenografted in Balb/c mouse assessed as tumour growth inhibition at 15 mg/kg, po administered daily and measured at day 18 relative to control | Homo sapiens | 2 | organism-based format | Scientific Literature | ||
| 20. | ALA4362226 | T | Toxicity in Balb/c mouse xenografted with human A549 cells assessed as effect on weight loss at 10 mg/kg, po measured up to 17 days | Mus musculus | 2 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!